Hitco Capacities

Overall, the general policy of the Hitco Group of Companies is to move toward a framework in which dependence on foreign suppliers is minimized, aiming for most production processes to be carried out domestically. To that end, the following capacities have been integrated into the holding’s structure.

Production of General and Specialized Pharmaceuticals at the Shamsabad Manufacturing Site

To date, Hitco Group and its subsidiaries have been engaged in contract manufacturing of pharmaceutical products — both domestic and licensed — through collaborations with reputable production partners. In line with its commitment to maintaining international production standards and fully implementing Good Manufacturing Practices (GMP), Hitco is nearing the completion of its own manufacturing facility in Shamsabad Industrial Zone, Tehran Province. This facility, expected to be operational within the coming months, is specifically designed for the production of solid and semi-solid dosage forms of pharmaceutical solutions.

Production of Hygiene, Cosmetic, and Skincare Products at Hitco Holding’s Manufacturing Facilities

The main objective of this integration is to internalize the overall production process of skincare, cosmetic, and hygiene products. Sourinet, as a modern and well-equipped manufacturing unit, is expected to become fully operational across all capacities in the near future.

Active Participation in Advancing New Biotechnological Therapies Within the Country

In addition to licensed production and technology transfer, Hitco Group is firmly committed to localizing advanced therapeutic tools, with the goal of improving access to treatment for Iranian patients suffering from rare and hard-to-treat diseases. In line with this vision, the Group’s leadership has made the strategic decision to invest in cutting-edge therapies such as gene therapy, human immunoglobulin production, and other life-saving medications. As a result, several knowledge-based companies have recently joined the Hitco family. One example is Kara Yakhteh Tajhiz Azma, a knowledge-based company specializing in gene therapy, with which Hitco began its collaboration. Today, this company is recognized as one of the leading players in the region in the field of genetic treatments. Supporting the localization of advanced medical therapies and providing pharmaceutical solutions through licensed production are both among Hitco Group’s core values.

Warehouse Standards

Given the organization’s core focus on health-related sectors, having a well-equipped and compliant warehouse is of critical importance. Such warehouses are inspected annually by relevant regulatory bodies, which typically apply strict criteria for issuing standard certifications. Hitco Group’s warehouse, which stores a wide range of products — including pharmaceuticals, medical equipment, dietary supplements, and active pharmaceutical ingredients (APIs) — has once again successfully obtained this certification, as it has in recent years. Following the Ministry of Health’s directives on storing health-related goods, and employing specialists in warehousing, have had the greatest effect on securing these approvals over the years.

About gene therapy

What is gene therapy?

Human gene therapy encompasses a set of advanced approaches through which the biological characteristics of living cells are modified to address specific therapeutic needs. In other words, it involves techniques that alter or manipulate a patient’s genes to enable advanced treatment of certain diseases. Kara Yakhteh Tajhiz Azma specializes primarily in the field of CAR T-Cell therapy.

What is CAR T-Cell therapy?

This gene therapy approach has proven effective in certain types of cancer, while it may not be effective in treating other diseases. T cells, which primarily support the immune system and its functions, are capable of identifying foreign substances in the body. They recognize these substances by detecting a specific protein on the surface of foreign cells, known as an antigen. Immune cells can identify and bind to antigens through their receptors. Cancer cells also carry antigens, but if your immune cells do not have the appropriate receptors, they cannot attach to those antigens and help destroy the cancer cells.

Chimeric Antigen Receptors (CARs)

In CAR T-cell therapy, T cells extracted from the patient’s blood are engineered to express special antigen receptors called Chimeric Antigen Receptors (CARs). Since antigens vary across different types of cancer, each CAR group must be specifically designed to target a particular cancer type. For example, in certain forms of leukemia or lymphoma, cancer cells express an antigen known as CD19. CAR T-cell therapies developed to treat these cancers are typically modified to bind to the CD19 antigen. Therefore, this type of therapy is not applicable to cancers that do not express the CD19 antigen.